Revenue Breakdown
Composition ()
No data
Revenue Streams
Jupiter Neurosciences Inc (JUNS) generates its revenue primarily from Premium Nutritional Supplements, which accounts for 100.0% of total sales, equivalent to $18.65K. Understanding this concentration is critical for investors evaluating how JUNS navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Jupiter Neurosciences Inc maintains a gross margin of 76.61%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -10524.34%, while the net margin is -11054.89%. These profitability ratios, combined with a Return on Equity (ROE) of -6529.17%, provide a clear picture of how effectively JUNS converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, JUNS competes directly with industry leaders such as QNRX and ACXP. With a market capitalization of $10.42M, it holds a leading position in the sector. When comparing efficiency, JUNS's gross margin of 76.61% stands against QNRX's N/A and ACXP's N/A. Such benchmarking helps identify whether Jupiter Neurosciences Inc is trading at a premium or discount relative to its financial performance.
